BioNTech SE (BNTX) Current Deferred Revenue (2018 - 2025)

BioNTech SE has disclosed Current Deferred Revenue across 8 years of filings, most recently posting $878.7 million for Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $878.7 million, up 178.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $878.7 million (up 178.85% YoY), and the FY2025 annual result was $852.9 million, up 170.65% from the prior year.
• Current Deferred Revenue came in at $878.7 million for Q4 2025 at BioNTech SE, down from $930.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.1 billion in Q2 2025 to a low of $48.9 million in Q1 2023.
• The 5-year median for Current Deferred Revenue is $384.0 million (2021), against an average of $454.6 million.
• Across the five-year window, Current Deferred Revenue plunged 77.29% in 2023 and surged 741.67% in 2024, its largest moves.
• BioNTech SE's Current Deferred Revenue stood at $212.9 million in 2021, then sank by 63.05% to $78.7 million in 2022, then jumped by 445.08% to $428.8 million in 2023, then decreased by 26.5% to $315.1 million in 2024, then surged by 178.85% to $878.7 million in 2025.
• The last three Current Deferred Revenue figures came in at $878.7 million (Q4 2025), $930.7 million (Q3 2025), and $1.1 billion (Q2 2025), per Business Quant data.